In studies investigating the resistance of glioblastoma to temozolomide (TMZ), overexpression of SNHG15 was associated with poor patient survival, and knockdown of SNHG15 effectively inhibited the tumorigenic properties of TMZ-R cells via the regulation of miR-627/CDK6 pathway, increasing TMZ-R cell sensitivity to TMZ as well as decreasing TMZ-R’s capacity to generate M2 GAM and glioma stem cells. Here, SNHG15 is linked to central nervous system cancer.